|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: May 2024
Volume 9 | Issue 5
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 96
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | Development and Validation of RP-HPLC Method for Estimation of Lumateperone Drug in pharmaceutical Dosage Form |
| Authors Name: | Rathod Ganesh Dhondiram |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_201997
|
| Published Paper Id: | IJNRD2307389 |
| Published In: | Volume 8 Issue 7, July-2023 |
| DOI: | |
| Abstract: | Lumateperone is a medication used to manage and treat schizophrenia and other neuropsychiatric disorders. It is a second-generation atypical antipsychotic medication that exhibits a novel mechanism of action. Lumateperone's mechanism of action involves simultaneous modulation of dopaminergic, serotonergic, and glutamatergic neurotransmission. This activity describes the indications, mechanism of action, and administration of lumateperone as a valuable treatment of schizophrenia. This activity will highlight the mechanism of action, adverse effect profile, and other key factors such as dosage and interactions for the interdisciplinary healthcare team responsible for treating individuals with schizophrenia and other neuropsychiatric disorders |
| Keywords: | |
| Cite Article: | "Development and Validation of RP-HPLC Method for Estimation of Lumateperone Drug in pharmaceutical Dosage Form", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 7, page no.d780-d791, July-2023, Available :http://www.ijnrd.org/papers/IJNRD2307389.pdf |
| Downloads: | 000118757 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRD2307389 Registration ID: 201997 Published In: Volume 8 Issue 7, July-2023 DOI (Digital Object Identifier): Page No: d780-d791 Country: Parbhani , Maharashtra , India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2307389 Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2307389 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn